Skip to content

Tongguan Capsules Prevents Post-Myocardial Infarction Left Ventricular Remodeling by Influencing Intestinal Flora and Blood Metabolomics Trial

Tongguan Capsules Prevents Post-Myocardial Infarction Left Ventricular Remodeling by Influencing Intestinal Flora and Blood Metabolomics Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043235
Enrollment
Unknown
Registered
2021-02-09
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventricular remodeling after acute myocardial infarction

Interventions

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for healthy subjects: 1. There was no abnormality in coronary angiography. 2. There is no abnormality in routine physical examination and examination. 3. No history of drug abuse or allergy, no history of alcohol addiction. 4. They are between 18 and 75 years old. 5. No obvious dietary preference. 6. In the past month, no antibiotics, steroids and other hormones, Chinese herbal medicine preparations, micro-ecological preparations or probiotics such as yogurt and coffee, strong tea. 7. Patients signed informed consent and were willing to accept the corresponding examination and treatment. Inclusion criteria for patients with ST-segment elevation MI: 1. It meets the diagnostic criteria of ST-segment elevation MI and chest pain with qi deficiency and blood stasis; 2. Between the ages of 18 and 75; 3. No obvious dietary preference; 4. Not using antibiotics, steroids and other hormones, Chinese herbal medicine preparations, microecological preparations, yogurt and other probiotics, coffee, strong tea in the past month. 5. The patient signed the informed consent and was willing to accept the corresponding examination and treatment.

Exclusion criteria

Exclusion criteria: 1. Cardiogenic shock patients, severe heart failure (cardiac function grade IV, or left ventricular ejection fraction and/or SCR >= 265umol/L); 3. Serious blood system diseases, nervous system or mental diseases, malignant tumors; 4. with other digestive system organic lesions (such as peptic ulcer); 5. People who are using or need continuous use of drugs that may affect gastrointestinal function (antidiarrhetics, intestinal flora regulating drugs, antibiotics, etc.); 6. People with a history of allergy to related drugs used in research and a history of severe food allergy; 7. Pregnant or lactating women; 8. are participating in other researchers.

Design outcomes

Primary

MeasureTime frame
LVEF;LVEDD;LVESD;MACE;

Secondary

MeasureTime frame
Intestinal probiotics;Intestinal tract pathogenic bacteria;TMAO;SC-Fas;TBA;

Countries

China

Contacts

Public ContactMinzhou Zhang

Guangdong Provincial Hospital of Chinese Medicine

minzhouzhang@yeah.net+86 13924266368

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026